Treatment Use: Electron IORT

Summary/Conclusion

This study provides 10-year outcome data of 770 stage I through III breast cancer patients who received intraoperative electron radiation therapy (IOERT) as a tumor bed boost preceding whole breast irradiation. After a median follow-up period of 121 months, 21 in-breast recurrences (2.7%) occurred with triple-negative and HER2fl subtypes as negative predictors. As confirmed in long-term follow-up, IOERT has been demonstrated to be a viable boost strategy in any risk constellation.

Summary/Conclusion

Authors Robert Krempien and Falk Roeder Abstract Despite the important improvements made in the fields of surgery, chemotherapy and radiation therapy, pancreatic cancer remains one of the most lethal malignancies. Improved outcomes with novel chemotherapy regimes led again to increased attention on the role of localized radiotherapy, since local tumor progression causes significant morbidity and mortality … Continued

Summary/Conclusion

The purpose of this work was to retrospectively evaluate survival and local control rates of triple-negative breast cancer subtypes classified as five marker negative (5NP) and core basal (CB), respectively, after breast-conserving surgery and intraoperative boost radiotherapy with electrons (IOERT) followed by whole breast irradiation.

Summary/Conclusion

Recently, interest has also grown in intraoperative radiation therapy (IORT), which treats the partial breast with a single dose of radiation using either low-energy x-rays or electrons, most commonly delivered at the time of surgery. These different modalities are likely to have certain tradeoffs with regard to their effectiveness and toxicity profiles, although these tradeoffs have yet to be completely described in the existing literature.

Summary/Conclusion

Authors AnnaPetoukhova, IrisRüssel, JulienneNijst-Brouwers, Kovan Wingerden, Jaapvan Egmond, DaphneJacobs, AndreasMarinelli, Joostvan der Sijp, PeterKoper, HenkStruikmans  Purpose The purpose of this study was to compare the delivered dose to the expected intraoperative radiation therapy (IORT) dose with in vivo dosimetry. For IORT using electrons in accelerated partial breast irradiation, this is especially relevant since a high dose is delivered in a single fraction. Methods For … Continued

Summary/Conclusion

These findings support the recent guidelines from the American Society for Radiation Oncology (ASTRO) supporting the use of electron IORT for low-risk patients.

Summary/Conclusion

After breast conservation surgery, SF or HfB may be an option for patients with early-stage breast cancer compared to conventional external beam radiotherapy.

Summary/Conclusion

In our current practice we consider the following preoperative factors to select patients suitable for IORT: age > 50 years, absence of lobular histology, tumor size ≤ 2 cm, pN0 or pNmic, according to APBI consensus statement, including also ki67 ≤ 20%, non triple negative receptor status and G1-G2

Summary/Conclusion

For patients with locally advanced primary or recurrent gynecologic cancers, prognosis is poor. Doses of EBRT required to treat either gross or microscopic disease in patients previously irradiated or treated surgically exceed doses that are tolerated by normal anatomic structures …

Summary/Conclusion

Objectives Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC. Whereas some patients remain unresectable on surgical exploration, others are able to undergo resection after intensive neoadjuvant treatment. We evaluated outcomes and toxicity associated … Continued